Is Atopic Dermatitis making you itch?

• A Phase 3, 4-week study reviewing the safety of a topical cream given QD in mild atopic dermatitis subjects

Study Benefits*

• Study the safety and efficacy of an investigational topical cream for mild to moderate atopic dermatitis
• Being studied in both children and adults
• The study drug is a PD4-inhibitor
• PD4 has been associated with higher production of pro-inflammatory mediators and lower production of the anti-inflammatory mediator IL-10
• Therefore, the study drug works to directly block the PD4 and block inflammation of the skin
• Non-steroidal topical cream with once daily dosing
• All study related care and medication provided
• Open label extension study available

Study Volunteers Must Meet the Following Criteria

• 6 years and older with a diagnosis of mild to moderate atopic dermatitis
• Not pregnant or breastfeeding or planning to do so

Study Participant Expectations

• 2-month study duration with 5 study visits
• Blood samples collected 3 times during course of study
• Optional medical photography portion of the study available
• Optional open label study available that allows participants to continue to receive the study treatment

Cost

• There is no cost to participate
• Patients who qualify may be compensated for time and travel